Robert Dugre

Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing novel drugs that are crossing the blood-brain barrier to treat brain diseases. These new Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention. Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the treatment of a wide range of brain diseases including brain cancers, lysosomal storage disorders, pain and others. The EPiC platform has been strongly validated in humans.